RT Journal Article SR Electronic T1 Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib Treatment JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 2203 OP 2207 DO 10.21873/anticanres.14996 VO 41 IS 4 A1 NIISATO, YUSUKE A1 MORIWAKI, TOSHIKAZU A1 FUKUOKA, SHOTA A1 MASUISHI, TOSHIKI A1 TAKASHIMA, ATSUO A1 KUMEKAWA, YOSUKE A1 KAJIWARA, TAKESHI A1 YAMAZAKI, KENTARO A1 ESAKI, TAITO A1 MAKIYAMA, AKITAKA A1 DENDA, TADAMICHI A1 HATACHI, YUKIMASA A1 SUTO, TAKESHI A1 SUGIMOTO, NAOTOSHI A1 SHIMADA, YASUHIRO YR 2021 UL http://ar.iiarjournals.org/content/41/4/2203.abstract AB Background/Aim: In later-line treatment of metastatic colorectal cancer (mCRC), trifluridine/tipiracil is often selected because regorafenib is difficult to use in patients with comorbidities such as thrombosis, hemorrhage, or cardiac events. However, the safety and efficacy of trifluridine/tipiracil in these patients is not clear. Patients and Methods: The clinical outcomes of trifluridine/tipiracil were retrospectively investigated in patients who were ineligible for regorafenib because of comorbidities. Results: Among the 27 patients who received trifluridine/tipiracil, many had comorbidities of deep venous thrombosis or hemorrhage. The median overall survival was 12.4 months, and the median progression-free survival was 2.8 months. The median overall survival was 7.7 months in 19 patients without subsequent regorafenib. Grade 3 or higher toxicities were found in 51% of patients. No treatment discontinuation because of comorbidities was observed. Conclusion: Trifluridine/tipiracil can be safely administered while maintaining efficacy in patients who were ineligible for regorafenib.